October 29, 2014 | The Israeli drug development company IntecPharma has secured Food & Drug Administration approval for a Phase III clinical trial on its Parkinson’s disease treatment. The Accordion Pill Levodopa is a gastro-retentive drug delivery system for the treatment of the common neurodegenerative disease. The company believes that the trial, which may be conducted together with a major pharmaceutical company, will be completed in the second half of 2015. IntecPharma is a publicly traded development stage biopharmaceutical company based in Jerusalem, Israel.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments